2. Clinically significant outcomes ‐ tricyclic antidepressants compared to placebo.
| Outcome measures | Gordon | Remington | Niederhofer | |
| TCA being investigated | Clomipramine | Clomipramine | Tianeptine | |
| Ratings conducted by: | Clinician Ratings | Clinician Ratings | Parent‐teacher Ratings | Clinician Ratings |
| Aberrant Behaviour Checklist (ABC) | Not significant | Eye contact P = 0.041 Inappropriate speech P = 0.042 Irritability P = 0.047 Hyperactivity P = 0.035 |
Not significant | |
| Childhood Autism Rating Scale (CARS) | Not significant | |||
| Childhood Global Assessment Scale (CGAS) | Not significant | |||
| Children's Psychiatric Rating Scale (CPRS) | P = 0.0001 | Not significant | ||
| CPRS ‐ Autism Relevant Subscale | P = 0.0001 | Overall ‐ not significant Irritability, anger, uncooperativeness P = 0.0001 Hyperactivity P = 0.001 |
||
| CPRS ‐ OCD and Anxiety Relevant Subscale | P = 0.001 | Not significant | ||
| Modified National Institute of Mental Health Global OCD and Anxiety Scale and Modified OCD Scale | Data not provided | |||
| Clinical Global Impression Scale | P = 0.0001 | Not significant | ||
| Symptom Checklist | Not significant | Two participants required dosage modification due to cardiac changes | ||
| Subjective Treatment Emergent Symptom Scale | Not significant | Increased drowsiness P = 0.025 Reduced activity P = 0.029 |
||
| Dosage Treament Emergent Symptom Scales (DOTES) | Not significant, but high drop‐out rates | |||
| Extrapyramidal Symptom Rating | Not significant | |||